Ignite Creation Date:
2024-05-06 @ 12:24 AM
Last Modification Date:
2024-10-26 @ 10:49 AM
Study NCT ID:
NCT01561911
Status:
COMPLETED
Last Update Posted:
2014-12-02
First Post:
2012-03-21
Brief Title:
A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 74 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment
Sponsor:
Organization:
Cancer Research UK
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
29
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: